Saturday 17 October 2026
Export VMD’s income statement to Excel — free account
Viemed Healthcare, Inc.
VMD Healthcare Medical Devices
Viemed Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $270.3 million, up 20.5% from fiscal 2024. In the quarter to June 2026, revenue grew 23.9%, EPS fell 12.5%, free cash flow fell 18.2% and total debt rose 65.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
9.48
0.27
−2.77%
Follow VMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
30.00 | 23.62 | 19.05 | 19.40 |
+8 more quarters Free account |
P/S ratio |
1.45 | 1.24 | 1.07 | 1.03 | |
P/FCF ratio |
12.66 | 9.74 | 10.29 | 11.26 | |
P/Operating CF |
27.42 | 43.85 | 15.67 | 14.28 | |
P/B ratio |
2.99 | 2.43 | 2.01 | 1.94 | |
Price to Tangible BV |
5.08 | 4.13 | 3.47 | 3.47 | |
EV/Sales |
1.43 | 1.23 | 1.07 | 1.07 | |
EV/EBITDA |
7.89 | 6.60 | 5.84 | 6.09 | |
EV/Operating CF |
7.11 | 6.19 | 5.54 | 5.62 | |
EV/FCF |
12.56 | 9.72 | 10.25 | 11.69 | |
Quick Ratio |
0.90 | 1.01 | 0.96 | 0.92 | |
Current Ratio |
1.13 | 1.22 | 1.18 | 1.13 | |
Net Debt/EBITDA |
(0.29) | (0.05) | (0.07) | 0.73 | |
Debt/Assets |
3.47% | 4.66% | 6.22% | 10.45% | |
Debt/Equity |
0.05 | 0.06 | 0.09 | 0.16 | |
Asset Turnover |
1.55 | 1.53 | 1.44 | 1.37 | |
Operating CF/Net income |
5.75 | 3.13 | 3.27 | 5.23 | |
Capex/Depreciation |
(0.96) | (0.71) | (0.99) | (0.79) | |
Interest Coverage |
20.13 | 15.14 | 23.62 | 11.98 | |
Research and Development Expense of Revenue |
0.65% | 0.77% | 0.78% | 1.08% | |
Selling, General and Administrative Expense of Revenue |
50.15% | 49.38% | 45.31% | 47.42% | |
Intangible Assets out of Total Assets |
0.29 | 0.30 | 0.30 | 0.30 | |
Share Based Compensation of Revenue |
2.60% | 3.25% | 3.02% | 3.03% | |
Graham Net Nets |
(0.01) | 0.00 | (0.02) | (0.06) | |
Graham Number |
5.71 | 5.77 | 5.69 | 5.26 | |
Earnings Yield |
3.33% | 4.23% | 5.25% | 5.15% | |
Free Cash Flow Yield |
7.90% | 10.27% | 9.72% | 8.88% | |
Revenue per Share |
2.04 | 1.96 | 1.96 | 1.86 | |
Operating CF per Share |
0.42 | 0.21 | 0.47 | 0.48 | |
Capex per Share |
(0.19) | (0.14) | (0.20) | (0.15) | |
Free Cash Flow per Share |
0.23 | 0.07 | 0.28 | 0.32 | |
Cash per Share |
0.28 | 0.25 | 0.35 | 0.29 | |
Shareholders Equity per Share |
3.82 | 3.79 | 3.69 | 3.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.82 | 3.79 | 3.69 | 3.51 | |
Free Cash Flow |
8.62 | 2.59 | 10.83 | 12.40 | |
Working Capital |
6.07 | 9.11 | 7.44 | 5.79 | |
Capital Expenditures |
(7.29) | (5.48) | (7.61) | (5.96) | |
Net Current Asset Value |
(4.29) | (1.75) | (7.14) | (16.88) | |
EV/EBIT |
17.81 | 14.92 | 14.07 | 15.91 | |
Capex to Sales |
0.09 | 0.07 | 0.10 | 0.08 | |
Price to Operating Income |
17.96 | 14.95 | 14.13 | 15.33 | |
| Other line items | |||||
Average Receivables |
29.39 | 28.98 | 25.36 | 28.19 | |
Average Payables |
9.62 | 8.26 | 6.33 | 7.34 | |
Average Inventory |
4.80 | 4.85 | 4.68 | 4.79 | |
Average Assets |
194.41 | 187.72 | 188.11 | 185.94 | |
Average Common Equity |
143.79 | 141.27 | 138.41 | 131.15 |
Columns are period end dates